PMID- 32317675
OWN - NLM
STAT- MEDLINE
DCOM- 20201126
LR  - 20210421
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Apr 21
TI  - Dysregulated EGFR pathway in serum in early-stage breast cancer patients: A case 
      control study.
PG  - 6714
LID - 10.1038/s41598-020-63375-z [doi]
LID - 6714
AB  - The epidermal growth factor receptor (EGFR) and its ligands are involved in 
      cancer pathogenesis and they might serve as circulating biomarkers. The current 
      study aims to investigate if abnormal pre-treatment serum levels of EGFR and EGFR 
      ligands are present in women with early-stage breast cancer and if up- or 
      downregulation of EGFR and EGFR ligands occur in defined patient subgroups. 
      Pre-treatment serum samples were obtained from 311 women with newly diagnosed 
      early-stage breast cancer and from 419 healthy women and analysed for EGFR and 
      the ligands: Epidermal growth factor (EGF), heparin-binding epidermal growth 
      factor (HBEGF), betacellulin (BTC), amphiregulin (AREG), and transforming growth 
      factor alpha (TGF-alpha). Previously, age-dependent 95% reference intervals for EGFR and 
      the EGFR ligands have been established based on the healthy women population. 
      S-EGFR, S-EGF, S-HBEGF, S-AREG, and S-TGFalpha were all significantly different in 
      women with breast cancer compared to healthy women (p < 0.05). Elevated S-EGFR, 
      according to the reference intervals, was present in 11.3% of breast cancer 
      patients, whereas decreased S-EGF was found in 11.6%. Elevated S-EGFR was 
      associated with estrogen receptor positivity of tumor (ER+) and a subgroup of 
      ER + breast cancer patients showed markedly elevated S-EGFR (>120 ng/mL).
FAU - Kjaer, Ina Mathilde
AU  - Kjaer IM
AD  - Department of Biochemistry and Immunology, Lillebaelt Hospital, University 
      Hospital of Southern Denmark, Vejle, Denmark. ina.mathilde.kjaer@rsyd.dk.
AD  - Department of Regional Health Research, Faculty of Health Sciences, University of 
      Southern Denmark, Odense, Denmark. ina.mathilde.kjaer@rsyd.dk.
FAU - Olsen, Dorte Aalund
AU  - Olsen DA
AD  - Department of Biochemistry and Immunology, Lillebaelt Hospital, University 
      Hospital of Southern Denmark, Vejle, Denmark.
FAU - Brandslund, Ivan
AU  - Brandslund I
AD  - Department of Biochemistry and Immunology, Lillebaelt Hospital, University 
      Hospital of Southern Denmark, Vejle, Denmark.
AD  - Department of Regional Health Research, Faculty of Health Sciences, University of 
      Southern Denmark, Odense, Denmark.
FAU - Bechmann, Troels
AU  - Bechmann T
AD  - Department of Regional Health Research, Faculty of Health Sciences, University of 
      Southern Denmark, Odense, Denmark.
AD  - Department of Oncology, Lillebaelt Hospital, University Hospital of Southern 
      Denmark, Vejle, Denmark.
FAU - Jakobsen, Erik Hugger
AU  - Jakobsen EH
AD  - Department of Oncology, Lillebaelt Hospital, University Hospital of Southern 
      Denmark, Vejle, Denmark.
FAU - Bogh, Soren Bie
AU  - Bogh SB
AD  - OPEN, Open Patient data Explorative Network, Department of Clinical Research, 
      University of Southern Denmark, Odense, Denmark.
FAU - Madsen, Jonna Skov
AU  - Madsen JS
AD  - Department of Biochemistry and Immunology, Lillebaelt Hospital, University 
      Hospital of Southern Denmark, Vejle, Denmark.
AD  - Department of Regional Health Research, Faculty of Health Sciences, University of 
      Southern Denmark, Odense, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20200421
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Ligands)
RN  - 0 (Receptors, Estrogen)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Breast Neoplasms/*blood/*pathology
MH  - Case-Control Studies
MH  - ErbB Receptors/*blood
MH  - Female
MH  - Humans
MH  - Ligands
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Receptors, Estrogen/metabolism
MH  - *Signal Transduction
PMC - PMC7174424
COIS- The authors declare no competing interests.
EDAT- 2020/04/23 06:00
MHDA- 2020/11/27 06:00
PMCR- 2020/04/21
CRDT- 2020/04/23 06:00
PHST- 2019/12/18 00:00 [received]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2020/11/27 06:00 [medline]
PHST- 2020/04/21 00:00 [pmc-release]
AID - 10.1038/s41598-020-63375-z [pii]
AID - 63375 [pii]
AID - 10.1038/s41598-020-63375-z [doi]
PST - epublish
SO  - Sci Rep. 2020 Apr 21;10(1):6714. doi: 10.1038/s41598-020-63375-z.